NCT05970302

XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

XELOX and Bevacizumab in Combination With Tislelizumab for First-Line Treatment of Patients With MSS/pMMR RAS-mutated Metastatic Colorectal Cancer (mCRC): A Single-arm, Phase II Study.

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 52 (estimated)
• Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to compare XELOX +Bev +Tislelizumab with standard chemotherapy，in MSS/pMMR-type RAS-mutated metastatic colorectal adenocarcinoma. The main questions it aims to answer are efficacy and safety of the regimen of XELOX +Bev +Tislelizumab. The investigators want to transform ras-mutated colorectal cancer into a "hot tumor" through the combination of anti-vascular therapy and chemotherapy, and then achieve better therapeutic effect through the combination with immunotherapy. Participants will receive the regimen of XELOX +Bev +Tislelizumab.

Conditions

• Tislelizumab
• Bevacizumab
• Oxaliplatin
• Capecitabine
• MSS/pMMR
• Metastatic Colorectal Cancer (mCRC)
• RAS-mutated
• First-Line

Interventions

Type	Name	Description
DRUG	Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine	Use the above medications on a regular basis.

Timeline

• Start date: 2023-07-07
• Primary completion: 2025-07-01
• Completion: 2026-07-01
• First posted: 2023-08-01
• Last updated: 2023-08-01

Locations

1 site across 1 country: China